Bill Text: NY S03350 | 2023-2024 | General Assembly | Introduced

New York Senate Bill 3350

Introduced

Bill Title: Requires practitioners who administer naloxone or another overdose reversal agent to a patient in the case of a suspected or confirmed overdose to report the administration of the agent to the prescription monitoring program registry.

Spectrum: Partisan Bill (Democrat 1-0)

Status: (Introduced) 2024-01-03 - REFERRED TO HEALTH [S03350 Detail]

Download: New_York-2023-S03350-Introduced.html




                STATE OF NEW YORK
        ________________________________________________________________________

                                          3350

                               2023-2024 Regular Sessions

                    IN SENATE

                                    January 30, 2023
                                       ___________

        Introduced by Sen. FERNANDEZ -- read twice and ordered printed, and when
          printed to be committed to the Committee on Health

        AN  ACT to amend the public health law, in relation to requiring practi-
          tioners who administer naloxone or another overdose reversal agent  to
          a  patient  in the case of a suspected or confirmed overdose to report
          the administration of the agent to the prescription monitoring program
          registry

          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:

     1    Section 1. Subdivision 9 of section 3343-a of the public health law is
     2  renumbered  subdivision  10  and a new subdivision 9 is added to read as
     3  follows:
     4    9. Administration of overdose reversal agents.  (a)  Any  practitioner
     5  who administers naloxone or another overdose reversal agent to a patient
     6  in the case of a suspected or confirmed overdose shall report the admin-
     7  istration  of  the agent to the prescription monitoring program registry
     8  within seventy-two hours of administration. Such  report  shall  contain
     9  the  following  information  if  available: (i) the name of the patient;
    10  (ii) the address of the patient; (iii) the date of birth of the patient;
    11  (iv) the time and place of the administration of the agent; and (v)  the
    12  identity of the person who administered the naloxone to the patient.
    13    (b) Any report made pursuant to the terms of this subdivision shall be
    14  considered to be made by the reporter in the course of his or her duties
    15  and shall be directly related to patient care.
    16    § 2. This act shall take effect January 1, 2025.



         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD08239-01-3